Has Rachel Nejem received payments from drug or device companies?

Yes. Drug and device makers reported $31,472 in general payments to Rachel Nejem across 177 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rachel Nejem did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rachel Nejem come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rachel Nejem

Adult Health · Lawrenceville, GANPI 1992045462

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $24,610 of the $31,472 with a category attached, or 78.2%. Dexcom, Inc. accounts for 75.5% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2021 at $20,968 and has fallen 99.9% since, to $14 in 2025. Among adult health clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$31,472in general payments, 2019–2025

Across 177 payments — averaging $177.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Dexcom, Inc.$24K
Novo Nordisk$6K
IBSA Pharma Inc.$514
Amgen$345
Bigfoot Biomedical Inc$212
Mannkind Corporation$155
plus $890 from 22 others

What the payments were for

Consulting fees$1,4004%
Speaking & faculty fees$24,61078%
Travel & lodging$2,0807%
Food & beverage$3,38111%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Dexcom, Inc.	68	$23,761
Novo Nordisk	29	$5,596
IBSA Pharma Inc.	2	$514
Amgen(2 entities)	7	$345
Bigfoot Biomedical Inc	4	$212
Mannkind Corporation	10	$155
Sanofi-aventis U.S. LLC	9	$136
AstraZeneca	7	$92
Xeris Pharmaceuticals, Inc.	4	$84
Abbott	5	$83
Corcept Therapeutics	3	$45
Insulet Corporation	2	$44
Lilly USA, LLC	3	$43
AbbVie	3	$36
Bayer	2	$35
Lifescan, Inc.	2	$35
BD	2	$35
Amarin Pharma, Inc.	2	$34
Radius Health, Inc.	2	$34
Tandem Diabetes Care, Inc.	2	$29
Medtronic	2	$22
Novartis	1	$18
Currax Pharmaceuticals LLC	1	$15
Vivus LLC	1	$15
Roche Diabetes Care, Inc.	1	$14
Antares Pharma, Inc.	1	$14
Esperion Therapeutics, Inc.	1	$14
Amneal Pharmaceuticals LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,472 in reported general payments places this provider in the 95th percentile of 577 adult health providers in Georgia.

See all adult health providers in Georgia →

Other adult health in Lawrenceville

Kristen CopelandLawrenceville$9K
Patricia KeeganAtlanta$224K
Diane WirthAtlanta$132K
Barbara WeberAtlanta$74K
Terry HackworthAtlanta$49K
Jenny DicksonCumming$39K
Melissa BaughcumAthens$23K
Kristine AdamsMarietta$21K
Jenina LagascaAtlanta$17K
Jennifer SheldonMacon$17K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →